In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Plans For Three Biosimilar Launches In Japan and US This Year

Executive Summary

Trastuzumab, rituximab and bevacizumab are slated for launch later this year as Pfizer builds out its biosimilar oncology offering.

You may also be interested in...



Pfizer Prepares For Year-End US Bevacizumab Launch

Pfizer has cleared the way to launching its Zirabev bevacizumab biosimilar in the US on 31 December this year following a patent-litigation settlement with Roche.

Pfizer To Merge Off-Patent Business With Mylan

Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.

Lyrica Rivals Are Rolled Out In The US

Several generic rivals to Pfizer’s Lyrica have hit the US market following the anti-seizure and pain brand’s loss of exclusivity.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1127945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel